Hemorrhagic syndrome and complement system: is there a connection? 616-002.151

Abstract

Summary. The interaction of hemostasis, complement and kinins provides non-specific protection of the body from damage of various nature. This review reflects the author’s attempt to understand these interactions based on literature review, as well as using the experience of the field offsite hematologic service in Moscow. The relationships of complement–hemostasis–kinins had been observed from the perspective of both the contact activation of coagulation, and cellular theory of hemostasis. The role of the Hageman factor as one of the binding agents between hemostasis and complement was noted. As a result of the analysis, direct association between the complement system and massive bleeding was not found, but the connection between the pathology of the complement system and hemostasis in the pathogenesis of the so-called thrombohemorrhagic states was noted. The review presents such critical conditions as amniotic fluid embolism, atypical hemolytic-uremic syndrome, heparin-induced thrombocytopenia type 2, describes current approaches to diagnosis and treatment.

References

1. Shavlyugin E.A., Khanin M.A. Mathematical model of complement system activation with the participation of contact system of blood coagulation. Fundamental’nye issledovaniya. 2012;(1):172– 8. (In Russ.).
2. Odintsov Yu.N., Perelmuter V.M. Biological functions of complement. Byulleten’ sibirskoj mediciny. 2007;6(2):72–82. (In Russ.).
3. Yarovaya G.A., Neshkova A.E. Past and present research on the kallikrein-kinin system (on the 90th anniversary of the discovery of the system). Bioorganicheskaya himiya. 2015;41(3):275–91. (In Russ.).
4. Maas C., Govers-Riemslag J.W.P., Bouma B.et al. Misfolded proteins activate Factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest. 2008;118(9):3208– 18. DOI: 10.1172/JCI35424.
5. Renne T., Pozgajová M., Grüner S. et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202(2):271–81. DOI: 10.1084/jem.20050664.
6. Renne T., Nieswandt B., Gailani D. The intrinsic pathway of coagulation is essential for thrombus stability in mice. Blood Cells Mol Dis. 2006; 36(2):148–51. DOI: 10.1016/j.bcmd.2005.12.014.
7. Kleinschnitz C., Stoll G., Bendszus M. et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med. 2006;203(3):513–8. DOI: 10.1084/jem.20052458.
8. Zeerleder S., Schloesser M., Redondo M. et al. Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency — a study on 73 subjects from 14 Swiss families. Thromb Haemost. 1999;82(4):1240–6.
9. Müller F., Gailani D., Renné T. Factor XI and XII as antithrombotic targets. Curr Opin Hematol. 2011;18(5):349–55. DOI: 10.1097/MOH.0b013e3283497e61.
10. Shebeko V.I. Endothelial dysfunction by complement activation. Immunopatologiya, allergologiya, infektologiya. 2000;(1):15–26. (In Russ.).
11. Kudlay D.A. Immunometabolic aspects of polytrauma pathogenesis: Avtoref. dis. dokt. med. nauk. Novosibirsk, 2007. 42 pp. (In Russ.).
12. Platonov A.E. The role of the complement system in the pathogenesis of meningococcal infection: Avtoref. dis. dokt. biol. nauk. Moscow, 1997. 27 pp. (In Russ.).
13. Silasi-Mansat R., Zhu H., Popescu N.I. аt al. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood. 2010;116(6):1002–10. DOI: 10.1182/blood-2010–02–269746.
14. Galstyan G.M., Krechetova A.V., Vasilyev S.A. et al. System of fibrinolysis in sepsis in patients with myelotoxic agranulocytosis. Anesteziologiya i reanimatologiya. 2012;(2):41–8. (In Russ.).
15. Trimarchi H., Duboscq C. Proteinuria: a cross road where the complement and the plasminogen-plasmin systems meet. J Integr Nephrol Androl. 2016;3(2):37–47. DOI: 10.4103/2394–2916.181217.
16. Fallah M., Viklund E., BäckmanA. et al. Plasminogen is a master regulator and a potential drug candidate for the healing of radiation wounds. Cell Death Dis. 2020;11(3):201. DOI: 10.1038/s41419– 020–2397–0.
17. Busardò F.P.,FratiP.,ZaamiS.,FineschiV.Amnioticfluidembolism pathophysiology suggests the new diagnostic armamentarium: β-tryptase and complement fractions C3-C4 are the indispensable working tools. Int J Mol Sci. 2015;16(3):6557–70. DOI: 10.3390/ijms16036557.
18. Tamura N., Kimura S., Farhana M. et al. C1 esterase inhibitor activity in amniotic fluid embolism. Crit Care Med. 2014;42(6):1392– 6. DOI: 10.1097/CCM.0000000000000217.
19. Bayalieva A. Zh., Fatkullin I.F., Shifman E.M. et al. Clinical guidelines for intensive therapy of amniotic fluid embolism during pregnancy and childbirth. Clinical guidelines. Moscow, 2016. 26 pp. (In Russ.). Available at: https://www.arfpoint.ru/wp-content/uploads/2014/06/Intensivnaya-terapiya-e-mbolii-okoloplodnimivodami-pri-beremennosti-i-rodah.pdf. [Accessed: 20.04.2020].
20. Pacheco L.D., Clark S.L., Klassen M., Hankins G.D.V. Amniotic fluid embolism: principles of early clinical management. Am J Obstet Gynecol. 2020;222(1):48–52. DOI: 10.1016/j.ajog.2019.07.036.
21. Loughran J.A., Kitchen T.L., Sindhakar S. et al. Rotational thromboelastometry (ROTEM®)-guided diagnosis and management of amniotic fluid embolism. Int J Obstet Anesth. 2019;38:127–30. DOI: 10.1016/j.ijoa.2018.09.001.
22. Rezai S., HughesA.C., LarsenT.B. et al. Atypical amniotic fluid embolism managed with a novel therapeutic regimen. Case Rep Obstet Gynecol. 2017;2017:8458375. DOI: 10.1155/2017/8458375.
23. Todo Y., Tamura N., Itoh H. et al. Therapeutic application of C1 esterase inhibitor concentrate for clinical amniotic fluid embolism: a case report. Clin Case Rep. 2015;3(7):673–5. DOI: 10.1002/ccr3.316.
24. Wu H.-D., Song Z.-K., Cao H.Y. et al. Successful treatment of amniotic fluid embolism complicated by disseminated intravascular coagulation with rivaroxaban: a case report. Medicine (Baltimore). 2020;99(4): e18951. DOI: 10.1097/MD.0000000000018951.
25. Kozlovskaya N. L., Prokopenko E. I., Emirova Kh.M., Serikova S. Yu. Clinical guidelines for the diagnosis and treatment of atypical hemolytic uremic syndrome. Nefrologiya i dializ. 2015;17(3):242– 64. (In Russ.).
26. Wada H., Matsumoto T., Suzuki K. et al. Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thromb J. 2018;16:14. DOI: 10.1186/s12959– 018–0168–2.
27. Emirova H. M., Orlova O. M., Muzurov A. L. et al. The experience of using Elizaria® for atypical hemolytic uremic syndrome. Pediatriya. 2019;98(5):225–9. (In Russ.). DOI: 10.24110/0031– 403X-2019–98–5–225–229.
28. Lavrishcheva I.V., Jakovenko A.A., Kudlay D.A. A case report of atypical hemolytic-uremic syndrome treatment with the first Russian eculizumab in adult patient. Urol Nephrol Open Access J. 2020;8(2):37–40.
29. Kulagin A., Ptushkin V., Lukina E. et al. Phase III clinical trial of Elizaria® and Soliris® in adult patients with paroxysmal nocturnal hemoglobinuria: results of comparative analysis of efficacy, safety, and pharmacological data. Blood. 2019;134(Suppl 1):3748. DOI: 10.1182/blood-2019–125693.
30. Demyanova K.A. The role of complement changes in the development of kidney damage in patients with microangiopathic syndromes: Avtoref. dis. kand. med. nauk. Moscow, 2018. 25 pp. (In Russ.).
31. CodyE.M., DixonB.P.Hemolytic uremic syndrome. Pediatr Clin North Am. 2019;66(1):235–46. DOI: 10.1016/j.pcl. 2018.09.011.
32. Dudarenko S.V., Ezhova O.A. Heparin-induced thrombocytopenia. Neotlozhnaya kardiologiya i kardiovaskulyarnye riski. 2018;2(1):252– 7. (In Russ.).
33. Cuker A., Arepally G.M., Chong B.H. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360–92. DOI: 10.1182/bloodadvances.2018024489.